Biocon

The company's subsidiary, Biocon Pharma, has received final approvals for its two ANDAs - Lenalidomide capsules and Dasatinib tablets - from the US Food and Drug Administration (US FDA). Lenalidomide is used to treat multiple myeloma, mantle cell lymphoma, and anemia in myelodysplastic syndromes in adults. Dasatinib tablets are used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Biocon Pharma also received tentative approval for its ANDA for Rivaroxaban tablets, which are used in the treatment of deep vein thrombosis and pulmonary embolism. Stock chart structure is looking positive as it gives a breakout of hammer pattern.